Ypsomed AG (Burgdorf, Switzerland) has focused on the development of pens and autoinjection systems for pre-filled syringes for delivery of insulin, GLP-1s, hormones, and autoimmune disease treatments. Two new cartridge-based pens for insulin are in development, the UnoPen, a disposable one-time-use system, and the ServoPen. A reusable device, the SevoPen is a spring–driven automatic, dial-and-dose pen, with a large display, says Ian Thompson, head of business development.
Ypsomed is planning a 2010 launch of the ClickFine Auto Protect Safety Pen Needle for use mainly for insulin injections performed in clinical settings, Thompson says.
For needle safety, a needle shield is activated when the needle is inserted into the skin and locks out when the needle is removed. A red bolt clearly signals that the needle has been used, he adds.
“All of our new platforms including the monodose dual-chamber pen and syringe-based auto-injector systems are designed with the patient in mind. We have focused on providing devices with the necessary patient-oriented feature set but that still allow the patient control over the injection process.”